Navigation Links
Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020
Date:12/9/2010

NEW YORK, Dec. 9, 2010 /PRNewswire/ --

Reportlinker.com announces that a new market research report is available in its catalogue:

Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020

http://www.reportlinker.com/p0332355/Prostate-Cancer---Italy-Drug-Forecasts-and-Treatment-Analysis-to-2020.html

Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020

SummaryGlobalData's pharmaceutical report, "Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020". The report is an essential source of information and analysis on the Italian prostate cancer therapeutics market. The report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. It identifies and analyzes the key trends shaping and driving the Italian prostate cancer therapeutics market, and analyzes the treatment usage patterns. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global prostate cancer sector. It quantifies the unmet need in the Italian prostate cancer therapeutics market, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The scope of the report includes:

- An overview of prostate cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.

- Annualized Italian prostate cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, forecast for 11 years to 2020.

- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.

- Competitor assessment including drug launch analysis and drug sales forecasts.

- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM (Life Cycle Management) activities and drug sales forecast.

- Analysis of unmet need in the market and target product profiles including opportunity for target products.

- Technology trends analytic framework to assess the strength of the pipeline.

- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, tyrosine kinase inhibitor, angiogenesis inhibitors and others.

- An overview of the most promising drugs including clinical study details, efficacy, safety, collaboration agreements, marketing rights and launch analysis.

- Analysis of the current and future market competition in the Italian Prostate Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Sanofi-aventis, Pfizer, Inc., AstraZeneca PLC, Bristol-Myers Squibb, Medivation, Takeda Pharmaceuticals and Dendreon Corporation.

- Analysis of licensing agreements during 2004-2010 in the prostate cancer therapeutics market. Merger and Acquisition (M&A analysis) which includes M&A deals by size and geography.

- Strategic assessment of the market through market impact analysis, future market scenario and company analysis.

- Direct quotes from key opinion leaders (KOL) or physicians in the prostate cancer therapeutics market in Italy.

Reasons to buyThe report will enhance your decision making capability. It will allow you to:

- Develop business strategies and perform superior market quantification analysis by

- Understanding the trends shaping and driving the Italian prostate cancer therapeutics market.

- Understanding the treatment preferences of physicians for each disease state and across treatment flow.

- Accessing market sizing forecasts and quantified growth opportunities in the Italian prostate cancer therapeutics market up to 2020.

- Quantifying the patient population in the Italian to better design product pricing and launch plans.

- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by

- Performing benchmarking analysis and growth opportunities against currently marketed products.

- Identifying market entry points based on safety, efficacy, and pricing parameters.

- Assessing competitiveness of products in the market by understanding the strengths and weaknesses of current competition.

- Develop and design your in-licensing and out-licensing strategies by

- Taking a comprehensive look at the disease pipeline and identifying the most promising paradigm-shifting products.

- Assessing the strength of pipeline based on first-in-class, me-too and generic products and their lifecycle management.

- Track drug sales in the Italian prostate cancer therapeutics market from 2001 to 2020.

- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.

- What's the next big thing in the Italian prostate cancer therapeutics market landscape? Identify, understand and capitalize.

1 Table of contents 3

1.1 List of Tables 6

1.2 List of Figures 7

2 Disease Overview 9

2.1 Overview 9

2.1.1 TNM (Tumor, Nodes, Metastasis) Staging System 9

2.1.2 Jewett-Whitmore system 10

2.2 Epidemiology 11

2.3 Etiology 11

2.4 Symptoms 11

2.4.1 Localized or Locally Advanced Prostate Cancer 11

2.4.2 Metastatic Prostate Cancer 12

2.5 Diagnosis 12

2.5.1 Digital Rectal Examination 12

2.5.2 Prostate Specific Antigen Test 13

2.5.3 Transrectal Ultrasound 13

2.5.4 Prostate Biopsy 13

2.6 Pathology 14

2.6.1 Grading 14

2.7 Treatment 14

2.7.1 Watchful Waiting 14

2.7.2 Radiation therapy 14

2.7.3 Surgery 15

2.7.4 Hormone therapy 16

2.7.5 Chemotherapy Options 17

2.7.6 Other Treatments Being Studied 17

2.8 Treatment Guidelines 18

3 Market Characterization 19

3.1 Italy 19

3.1.1 Market Size 19

3.1.2 Drivers & Barriers 25

3.1.3 Impact on the Market 27

3.1.4 Forecasts 28

3.1.5 Drug Sales 34

3.1.6 Pricing and Reimbursements 38

4 Competitor Assessment 39

4.1 Strategic Competitor Assessment 39

4.1.1 Overview 39

4.1.2 Benchmarking 39

4.1.3 Current Competitor Assessment 43

4.2 Launch Analysis and Sales Forecasts 45

4.3 Product Profiles 46

4.3.1 Taxotere (docetaxel) 47

4.3.2 Casodex (Bicalutamide) 51

4.3.3 Zoladex (Goserelin) 57

4.3.4 Eligard (leuprolide acetate) 59

4.3.5 Firmagon (degarelix) 64

4.3.6 Novantrone (Mitoxantrone hydrochloride) 66

4.3.7 Emcyt (estramustine) 69

4.3.8 Trelstar (triptorelin) 71

4.3.9 Eulexin 72

4.3.10 Delestrogen 74

4.3.11 Gynodiol 76

4.3.12 Estrace tablet 77

4.3.13 Tace 78

4.3.14 Nilandrone 79

4.3.15 Premarin 80

4.3.16 Sales Forecast for Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol 81

5 Pipeline Assessment 82

5.1 Overview 82

5.2 Pipeline Analysis by Phase of Development 83

5.3 Pipeline by Mechanism of Action 84

5.4 Strategic Pipeline Assessment 85

5.4.1 Technology Trends Analytical Framework 85

5.5 Trends in Prostate Cancer Pipeline 86

5.5.1 More Clarity on the Origin of Prostate Cancer Will Help in Identifying Novel Targets for Prostate Cancer Drugs 86

5.5.2 Molecules with Novel Mechanism of Action Strengthening Prostate Cancer Pipeline 86

5.5.3 Failure of Key Molecules to Achieve Positive Results in Phase III Development 87

5.6 Partners in Research and Development 87

5.6.1 Licensing Agreements by Phase of Development 88

5.6.2 Licensing Agreements by Geography 91

5.6.3 Licensing Agreements: Technology Licensing Agreements in Prostate Cancer 91

5.7 Most Promising Drugs' Profiles 92

5.7.1 Provenge (sipuleucel-T) 94

5.7.2 Jevtana (cabazitaxel) 96

5.7.3 Aflibercept (VEGF Trap) 97

5.7.4 Ipilimumab 100

5.7.5 Abiraterone Acetate (CB7630) 102

5.7.6 Zibotentan (ZD4054) 105

5.7.7 Sprycel (dasatinib) 108

5.7.8 MDV3100 110

5.8 Prostate Cancer Pipeline – Pre-clinical Phase 112

5.9 Prostate Cancer Pipeline – Phase I 114

5.10 Prostate Cancer Pipeline – Phase II 117

5.11 Prostate Cancer Pipeline – Phase III 125

5.12 Key Takeaway 127

6 Unmet Need and Target Product Profile 128

6.1 Unmet Need 130

6.1.1 Hormone-independent Metastatic Prostate Cancer Therapy 131

6.1.2 Hormone-dependent Metastatic Prostate Cancer Therapy 132

6.2 Opportunity for Target Product 132

6.3 Target Product Profile 134

6.3.1 Ideal Characteristics 134

6.3.2 Target Product Description 135

6.4 Key Takeaway 135

7 Strategic Assessment 136

7.1 Key Events Impacting the Future Market 136

7.2 Market Impact Analysis 137

7.3 Future Market Scenario 137

7.4 Company Analysis 139

7.4.1 Market Leadership 139

7.4.2 Future Players in the Market 139

7.5 Key Takeaway 140

8 Company Profiles 141

8.1 Sanofi-aventis 141

8.1.1 Business Description 141

8.1.2 Financial Overview 143

8.1.3 SWOT Analysis 143

8.1.4 Oncology Focus 148

8.2 Pfizer Inc. 149

8.2.1 Business Description 149

8.2.2 Financial Overview 150

8.2.3 SWOT Analysis 150

8.2.4 Oncology Focus 157

8.3 AstraZeneca 159

8.3.1 Business Description 159

8.3.2 Financial Overview 160

8.3.3 SWOT Analysis 161

8.3.4 Oncology Focus 165

8.4 Bristol-Myers Squibb 167

8.4.1 Business Description 167

8.4.2 Financial Overview 168

8.4.3 SWOT Analysis 168

8.4.4 Oncology Focus 174

8.5 Medivation 176

8.5.1 Business Description 176

8.5.2 SWOT Analysis 176

8.5.3 Oncology Focus 179

8.6 Takeda Pharmaceuticals 180

8.6.1 Business Description 180

8.6.2 SWOT Analysis 180

8.7 Dendreon Corporation 182

8.7.1 Business Description 182

8.7.2 SWOT Analysis 182

8.8 Johnson and Johnson 185

8.8.1 Business Description 185

8.8.2 SWOT Analysis 187

8.8.3 Oncology Focus 193

8.9 Auron Healthcare GmbH 194

8.9.1 Business Description 194

8.10 Oncogenex Pharmaceuticals, Inc. 194

8.10.1 Business Description 194

8.11 Agennix AG 194

8.11.1 Business Description 194

8.12 GTx, Inc. 195

8.12.1 Business Description 195

8.13 GlaxoSmithKline plc. 195

8.13.1 Business Description 195

8.13.2 Financial Overview 196

8.13.3 SWOT Analysis 196

8.13.4 Oncology Focus 202

9 M&A Analysis 204

9.1 Key Highlights 204

9.2 Key Deals' Analysis 206

9.2.1 Johnson & Johnson Acquires Cougar Biotechnology 206

9.2.2 Endo Pharmaceuticals Acquires Indevus Pharmaceuticals 206

9.2.3 Tolmar Holding Acquires QLT USA from QLT 206

9.2.4 Biomarin Pharmaceutical to Acquire Lead therapeutics 206

9.2.5 Isis Pharmaceuticals Reacquires Rights to Cancer Drug from Eli Lilly & Co. 206

9.2.6 Quest PharmaTech Acquires Late-stage Immunotherapeutic Antibody Pipeline from Paladin Labs 207

9.2.7 VaxOnco Acquires Rights to Onyvax-P Cell Vaccine From Onyvax 207

9.2.8 GPC Biotech Merges with Agennix 207

9.2.9 Eli Lilly Acquires ImClone 207

9.2.10 BBM Holdings Acquires YM BioSciences 207

9.2.11 Sagent Pharmaceuticals Acquires Injectable Generic Drug Applications of Spectrum Pharmaceuticals 208

9.3 M&A Deals by Geography 208

9.4 M&A Deals by Deal Size 209

10 Expert Opinion 210

10.1 Italy 210

11 Appendix 211

11.1 Market Definitions 211

11.2 Abbreviations 211

11.3 Research Methodology 213

11.3.1 Coverage 213

11.3.2 Secondary Research 214

11.3.3 Forecasting 214

11.3.4 Primary Research 217

11.3.5 Expert Panel validation 217

11.3.6 Contact Us 217

11.4 Disclaimer 217

11.5 Sources 2181.1 List of Tables

Table 1: Prostate Cancer Therapeutics Market, Global, Staging of the Prostate Cancer, 2010 10

Table 2: Prostate Cancer, Global, Age Related PSA Levels (ng/ml), 2010 13

Table 3: Prostate Cancer Therapeutics Market, Italy, Sales Value ($m), 2001-2009 19

Table 4: Prostate Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2001-2009 20

Table 5: Prostate Cancer Therapeutics Market, Italy, Patient Volume ('000s), 2001-2009 22

Table 6: Prostate Cancer Therapeutics Market, Italy, Treatment Usage Patterns ('000s), 2001-2009 23

Table 7: Prostate Cancer Therapeutics Market, Italy, Sales Value ($m), 2009-2020 28

Table 8: Prostate Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2009-2020 29

Table 9: Prostate Cancer Therapeutics Market, Italy, Patient Volume ('000s), 2009-2020 30

Table 10: Prostate Cancer Therapeutics Market, Italy, Treatment Usage Patterns ('000s), 2009-2020 31

Table 11: Prostate Cancer Therapeutics Market, Italy, Hormone-Refractory Prostate Cancer Drug Sales ($m), 2001-2010 35

Table 12: Prostate Cancer Therapeutics Market, Italy, Hormone-Refractory Prostate Cancer Drug Sales ($m), 2011-2020 35

Table 13: Prostate Cancer Therapeutics Market, Italy, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2001-2010 37

Table 14: Prostate Cancer Therapeutics Market, Italy, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2011-2020 37

Table 15: Prostate Cancer, Global, Clinical Endpoints for Benchmarking, 2010 40

Table 16: Prostate Cancer, Global, Chemotherapy, Safety Profile of Standard Care Treatment, 2010 41

Table 17: Prostate Cancer, Global, Hormone Therapy, Safety Profile of Standard Care Treatment, 2010 42

Table 18: Prostate Cancer, Global, Casodex, Incidence of Adverse Effects, 2010 52

Table 19: Prostate Cancer, Global, Eligard, Effect on PSA Level, 2010 60

Table 20: Prostate Cancer, Global, Eligard, Incidence of Adverse Effects, 2010 61

Table 21: Prostate Cancer, Global, Eligard, Regulatory Approval by Region 62

Table 22: Prostate Cancer, Global, Licensing Agreements, 2009-2010 90

Table 23: Prostate Cancer, Global, Technology Licensing Agreements Description, 2010 92

Table 24: Prostate Cancer, Global, Most Promising Drugs Under Clinical Development, 2010 92

Table 25: Prostate Cancer, Global, Pre-clinical Phase Pipeline, August 2010 112

Table 26: Prostate Cancer, Global, Phase I Pipeline, August 2010 114

Table 27: Prostate Cancer, Global, Phase II Pipeline, August 2010 117

Table 28: Prostate Cancer, Global, Phase III Pipeline, August 2010 125

Table 29: Prostate Cancer, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010 134

Table 30: Prostate Cancer, Global, Description of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010 135

Table 31: Prostate Cancer, Johnson & Johnson, Oncology Late Stage Pipeline by Indication, 2010 193

Table 32: Prostate Cancer, Global, Auron Healthcare, Key Pipeline Products, 2010 194

Table 33: Prostate Cancer, Global, M&A Deals by Geography, 2010 2041.2

List of FiguresFigure 1: Prostate Cancer Therapeutics Market, Global, Treatment Guidelines, 2010 18

Figure 2: Prostate Cancer Therapeutics Market, Italy, Sales Value ($m), 2001-2009 19

Figure 3: Prostate Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2001-2009 20

Figure 4: Prostate Cancer Therapeutics Market, Italy, Patient Volume ('000s), 2001-2009 22

Figure 5: Prostate Cancer Therapeutics Market, Italy, Treatment Usage Patterns ('000s), 2001-2009 23

Figure 6: Prostate Cancer Therapeutics Market, Italy, Market Drivers and Restraints, 2009 25

Figure 7: Prostate Cancer Therapeutics Market, Italy, Historical Events Impact on the Market, 2010 27

Figure 8: Prostate Cancer Therapeutics Market, Italy, Sales Value ($m), 2009-2020 28

Figure 9: Prostate Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2009-2020 29

Figure 10: Prostate Cancer Therapeutics Market, Italy, Patient Volume ('000s), 2009-2020 30

Figure 11: Prostate Cancer Therapeutics Market, Italy, Treatment Usage Patterns ('000s), 2009-2020 31

Figure 12: Prostate Cancer Therapeutics Market, Italy, Future Market Drivers and Restraints, 2009-2020 33

Figure 13: Prostate Cancer Therapeutics Market, Italy, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2020 34

Figure 14: Prostate Cancer Therapeutics Market, Italy, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2001-2020 36

Figure 15: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Chemotherapy Drugs, 2010 43

Figure 16: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Hormone Therapy Drugs, 2010 44

Figure 17: Prostate Cancer Therapeutics Market, Italy, Sales Forecast by Therapies, 2001-2020 45

Figure 18: Prostate Cancer, Global, Taxotere, Chemical Structure 47

Figure 19: Prostate Cancer, Global, Taxotere, LCM Activities, 2004-2010 49

Figure 20: Prostate Cancer, Italy, Taxotere, Sales ($m), 2004-2020 50

Figure 21: Prostate Cancer, Global, Casodex, Chemical Structure 51

Figure 22: Prostate Cancer, Global, Casodex, LCM Activities, 1995-2010 55

Figure 23: Prostate Cancer, Italy, Casodex, Sales ($m), 1995-2020 56

Figure 24: Prostate Cancer, Global, Zoladex, Chemical Structure 57

Figure 25: Prostate Cancer, Italy, Zoladex, Sales Forecast ($m), 1998-2020 58

Figure 26: Prostate Cancer, Global, Eligard , Chemical Structure 59

Figure 27: Prostate Cancer, Italy, Leuprolide (Eligard), Sales Forecast ($m), 2006-2020 63

Figure 28: Prostate Cancer, Global, Firmagon, Chemical Structure 64

Figure 29: Prostate Cancer, Italy, Firmagon, Sales Forecast ($m), 2009-2020 65

Figure 30: Prostate Cancer, Global, Novatrone, Chemical Structure 66

Figure 31: Prostate Cancer, Italy, Mitoxantrone, Sales Forecast ($m), 2001-2020 68

Figure 32: Prostate Cancer, Global, Emcyt, Chemical Structure 69

Figure 33: Prostate Cancer, Italy, Estramustine, Sales Forecast ($m), 2001-2020 70

Figure 34: Prostate Cancer, Global, Trelstar, Chemical Structure 71

Figure 35: Prostate Cancer, Global, Eulexin, Chemical Structure 72

Figure 36: Prostate Cancer, Global, Delestrogen, Chemical Structure 74

Figure 37: Prostate Cancer, Global, Gynodiol, Chemical Structure 76

Figure 38: Prostate Cancer, Global, Estrace, Chemical Structure 77

Figure 39: Prostate Cancer, Global, Tace, Chemical Structure 78

Figure 40: Prostate Cancer, Global, Nilandrone, Chemical Structure 79

Figure 41: Prostate Cancer, Global, Premarin, Chemical Structure 80

Figure 42: Prostate Cancer, Italy, Combined sales of Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol, Sales Forecast ($m), 2001-2020 81

Figure 43: Prostate Cancer, Global, Clinical Trials by Therapy, 2010 82

Figure 44: Prostate Cancer, Global, Clinical Trials by Phase of Development, 2010 83

Figure 45: Prostate Cancer, Global, Pipeline by Mechanism of Action, 2010 84

Figure 46: Prostate Cancer, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010 85

Figure 47: Prostate Cancer, Global, Technology Trends Description of Pipeline Drugs, 2010 86

Figure 48: Prostate Cancer, Global, Licensing Agreements by Phase of Development, 2009-2010 88

Figure 49: Prostate Cancer, Global, Licensing Agreements by Geography, 2010 91

Figure 50: Prostate Cancer, Italy, Provenge, Sales Forecast ($m), 2012-2020 95

Figure 51: Prostate Cancer, Italy, Jevtana, Sales Forecast ($m), 2011-2020 97

Figure 52: Prostate Cancer, Global, Aflibercept, Chemical Structure 98

Figure 53: Prostate Cancer, Italy, Aflibercept, Sales Forecast ($m), 2014-2020 99

Figure 54: Prostate Cancer, Italy, Ipilimumab , Sales Forecast ($m), 2014-2020 101

Figure 55: Prostate Cancer, Global, Abiraterone, Chemical Structure 102

Figure 56: Prostate Cancer, Italy, Abiraterone, Sales Forecast ($m), 2013-2020 104

Figure 57: Prostate Cancer, Global, Zibotentan, Chemical Structure 105

Figure 58: Prostate Cancer, Italy, Zibotentan , Sales Forecast ($m), 2013-2020 107

Figure 59: Prostate Cancer, Italy, Sprycel , Sales Forecast ($m), 2013-2020 109

Figure 60: Prostate Cancer, Global, MDV3100, Chemical Structure 110

Figure 61: Prostate Cancer, Italy, MDV3100 , Sales Forecast ($m), 2013-2020 111

Figure 62: Prostate Cancer, Global, Median Overall Survival for Hormone-independent Metastatic Prostate Cancer Patients, 2010 128

Figure 63: Prostate Cancer, Global, Median Overall Survival for Hormone-dependent Metastatic Prostate Cancer Patients, 2010 129

Figure 64: Prostate Cancer, Global, Hormone-dependent Metastatic Prostate Cancer Patients Achieving Castrate Level Testosterone Level in 28-30 Days (%), 2010 129

Figure 65: Prostate Cancer, Italy, Prostate Cancer, Opportunity and Unmet Need, 2010 130

Figure 66: Prostate Cancer, Italy, Hormone-independent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 133

Figure 67: Prostate Cancer, Italy, Hormone-dependent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 133

Figure 68: Prostate Cancer, Global, Key Events Impacting the Future Market 136

Figure 69: Prostate Cancer, Italy, Implications for Future Market Competition, 2010 137

Figure 70: Prostate Cancer, Global, Future Players in the Market, 2010 139

Figure 71:Prostate Cancer, Sanofi-aventis, Major Pharmaceutical Drugs 2010 141

Figure 72: Prostate Cancer, Sanofi-aventis Pasteur, Diseases Under Each Vaccination Area 2010 142

Figure 73: Prostate Cancer, Global, Sanofi-aventis, SWOT Analysis, 2010 143

Figure 74: Prostate Cancer, Sanofi-aventis, Therapeutic Segment Share of Pipeline 2010 148

Figure 75: Prostate Cancer, Global, Pfizer, SWOT Analysis 2010 150

Figure 76: Prostate Cancer, Pfizer, Distribution of Pipeline by Phase, 2010 157

Figure 77: Prostate Cancer, Pfizer, Therapeutic Segment Share of Pipeline 2010 158

Figure 78: Prostate Cancer, Astrazeneca, Key Products Portfolio 2010 160

Figure 79: Prostate Cancer, Global, AstraZeneca, SWOT Analysis 2010 161

Figure 80: Prostate Cancer, AstraZeneca, Oncology Products for Different Cancers 2010 165

Figure 81: Prostate Cancer, AstraZeneca, Distribution of Pipeline, by Phase, 2010 166

Figure 82: Prostate Cancer, AstraZeneca, Therapeutic Segment Share of Pipeline 2010 166

Figure 83: Prostate Cancer, Bristol-Myers Squibb, Key Products Portfolio 2010 167

Figure 84: Prostate Cancer, Global, Company Bristol-Myers Squibb, SWOT Analysis, 2010 168

Figure 85: Prostate Cancer, Bristol-Myers Squibb, Distribution of Pipeline by Phase, 2010 174

Figure 86: Prostate Cancer, Bristol-Myers Squibb, Therapeutic Segment Share of Pipeline 2010 175

Figure 87: Prostate Cancer, Global, Medivation, SWOT Analysis 2010 176

Figure 88: Prostate Cancer, Global, Takeda Pahrmaceuticals, SWOT Analysis 2010 180

Figure 89: Prostate Cancer, Global, Dendreon Corporation, SWOT Analysis 2010 182

Figure 90: Prostate Cancer, Global, Johnson and Johnson, SWOT Analysis 2010 187

Figure 91: Prostate Cancer, Johnson & Johnson, Late Stage Pipeline by Therapy Area, 2010 193

Figure 92: Prostate Cancer, Global, GlaxoSmithKline, SWOT Analysis 2010 196

Figure 93: Prostate Cancer, GlaxoSmithKline, Distribution of Pipeline by Phase, 2010 202

Figure 94: Prostate Cancer, GlaxoSmithKline, Therapeutic Segment Share of Pipeline 2010 203

Figure 95: Prostate Cancer, Global, M&A Deals by Geography of Target Companies, 2010 208

Figure 96: Prostate Cancer, Global, M&A Deals by Deal Size, 2010 209

Figure 97: Prostate Cancer, Italy, Key Data Inputs from KOL Interviews, July 2010 210

Figure 99: GlobalData Market Forecasting Model 216

Companies mentioned Sanofi-aventis

Pfizer Inc.

AstraZeneca

Bristol-Myers Squibb

Medivation

Takeda Pharmaceuticals

Dendreon Corporation

Johnson and Johnson

Auron Healthcare GmbH

Oncogenex Pharmaceuticals, Inc.

Agennix AG

GTx, Inc.

GlaxoSmithKline plc.

To order this report:Drug and Medication Industry: Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020

Drug and Medication Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Nicolas BombourgReportlinkerEmail: nbo@reportlinker.com US: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds Asia-Pacific Endoscopy Devices Market Outlook to 2016
2. Reportlinker Adds North America Neurology Devices Market Outlook to 2016
3. Reportlinker Adds Europe Cardiovascular Devices Market Outlook to 2016
4. Reportlinker adds Europe Orthopedic Devices Market Outlook to 2016
5. Reportlinker Adds Europe Neurology Devices Market Outlook to 2016
6. Reportlinker Adds Europe Hospital Supplies Market Outlook to 2016
7. Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016
8. Reportlinker Adds Medical Polymers Market to 2015 - Polyvinyl Chloride (PVC) Dominating the Medical Devices and Packaging Markets
9. Reportlinker Adds Diabetes Market to 2016 - Biguanides and Insulin Analogs will be the Largest Selling Anti-Diabetic Drugs
10. Reportlinker Adds China Pharmaceutical Market Overview
11. Reportlinker Adds Pharmaceutical Industry - 2010 Yearbook - Therapeutic Market Landscape, Key Pipeline Drugs, Top Pharma Companies and Key Mergers and Acquisitions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 2016  Kindred Biosciences, Inc. (NASDAQ: KIN ), ... lives of pets, today announced the submission to FDA ... Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive ... Zimeta for the control of pyrexia (fever) in horses ... --> --> The Chemistry, Manufacturing, and ...
(Date:2/11/2016)... , Feb. 11, 2016   Health 2.0 ... of new health technologies, announced today " 10 Year ... in health tech over the past ten years.   ... nearly a decade, Health 2.0 has served as the ... and connected with thousands of technologies, companies, innovators, and ...
(Date:2/11/2016)... 11, 2016  MiMedx Group, Inc. (NASDAQ: MDXG ... membrane and other birth tissues, human skin and bone, ... market advanced products and therapies, announced today that it ... Healthcare Conference in New York , ... Michael J. Senken , Chief Financial Officer and ...
Breaking Medicine Technology:
(Date:2/13/2016)... Angeles, California (PRWEB) , ... February 13, 2016 , ... ... help landing a date for the big day. A great outfit, flawless hair, and ... ashtray, they might as well resign themselves to a night at home with Rover. ...
(Date:2/13/2016)... Viejo, CA (PRWEB) , ... February 13, 2016 , ... ... ember particle overlays to footage all within Final Cut Pro X. Each user can ... control over 3D rotation, angle of view, blur, focus offset, hue, saturation, value, contrast, ...
(Date:2/13/2016)... ... February 13, 2016 , ... Christie Medical ... in-kind gift of a VeinViewer® Vision vein finder for the nursing ... start an IV and draw blood, combining technology with traditional technique. , “VeinViewer ...
(Date:2/13/2016)... ... , ... DDi , a Makro company, makes it ... expertise in eClinical Solutions. DDi has built its solution competency with a unique ... clients. DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains by ...
(Date:2/12/2016)... ... February 12, 2016 , ... The law firm of Morrow, Morrow, Ryan & ... purpose of these scholarships is to encourage applicants to pursue a degree in their ... these two parishes. , “We have available jobs in St. Landry and Evangeline ...
Breaking Medicine News(10 mins):